Basilea Pharmaceutica  has secured a BARDA contract of up to $159m to advance ceftibuten-ledaborbactam etzadroxil, its recently in-licensed oral, Phase III-ready antibiotic for complicated urinary tract infections (cUTIs). The agreement replaces the original BARDA deal with the licensee Venatorx (October 2023) and provides $6m in committed near-term funding, with a further up to $153m in milestone-based payments, including support for the planned Phase III programme.  Edison

Basilea Pharmaceutica ’s H125 results reflected strong sales traction, with revenues up 36.3% y-o-y to CHF104m, underpinned by 21.7% growth in royalties. A key strategic milestone was the US launch of Zevtera, diversifying Basilea’s revenue base and de-risking future sales. Post-period developments (initiation of the second Phase III trial for fosmanogepix and acquisition of a novel oral antibacterial) indicate growing pipeline momentum, with R&D support from BARDA. Full-year

Target Healthcare REIT Ltd (THRL)  operates in a structurally supported market with a growing elderly population and the need to improve...

Indexed rent reviews continue to drive earnings growth and property valuation uplifts at  Target Healthcare REIT Ltd (THRL) . Meanwhile,...

Basilea Pharmaceutica  has continued its strong momentum into 2025, announcing the receipt of a CHF1.2m milestone payment for Cresemba...

H224 continues to be a rewarding period for  Basilea Pharmaceutica , with the announcement of a third successive milestone payment for...

Basilea Pharmaceutica ’s H124 results reflect strong momentum across its pipeline and  Edison Group  expects the pace to accelerate in...

The uptrend in Cresemba sales in Asia-Pacific and China triggered the receipt of  Basilea Pharmaceutica ’s third milestone payment of...

SIGA Technologies  announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in...

Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the...

ALG Newsletter - Can we make NHI more affordable? We look at the signing of the NHI Bill from a slightly different perspective. Can...

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of...